How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.
Clinical management
Myelodysplastic neoplasms
Tailored approaches
Treatment options
Journal
Clinical hematology international
ISSN: 2590-0048
Titre abrégé: Clin Hematol Int
Pays: England
ID NLM: 101759455
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
28
09
2022
accepted:
14
11
2022
medline:
28
12
2022
pubmed:
28
12
2022
entrez:
27
12
2022
Statut:
ppublish
Résumé
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of clonal disorders characterized by a high degree of clinical and molecular heterogeneity, and an invariable tendency to progress to acute myeloid leukemia. MDS typically present in the elderly with cytopenias of different degrees and bone marrow dysplasia, the hallmarks of the disease. Allogeneic hematopoietic stem cell transplant is the sole curative approach to date. Nonetheless, given the disease's demographics, only a minority of patients can benefit from this procedure. Currently used prognostic schemes such as the Revised International Prognostic Scoring System (R-IPSS), and most recently the molecular IPSS (IPSS-M), guide clinical management by dividing MDS into two big categories: lower- and higher-risk cases, based on a cut-off score of 3.5. The main clinical problem of the lower-risk group is represented by the management of cytopenias, whereas the prevention of secondary leukemia progression is the goal for the latter. Herein, we discuss the non-transplant treatment of MDS, focusing on current practice and available therapeutic options, while also presenting new investigational agents potentially entering the MDS therapeutic arsenal in the near future.
Identifiants
pubmed: 36574201
doi: 10.1007/s44228-022-00024-4
pii: 10.1007/s44228-022-00024-4
pmc: PMC10063738
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
8-20Informations de copyright
© 2022. The Author(s).
Références
Leuk Res. 2019 Sep;84:106191
pubmed: 31386932
Leukemia. 2016 Nov;30(11):2214-2220
pubmed: 27311933
PLoS One. 2016 Nov 8;11(11):e0166245
pubmed: 27824923
Leuk Lymphoma. 2015 Apr;56(4):887-95
pubmed: 24956145
Leuk Lymphoma. 2012 Aug;53(8):1558-60
pubmed: 22280532
Blood Adv. 2022 Aug 16;:
pubmed: 35973199
Blood. 2011 Oct 6;118(14):3765-76
pubmed: 21753188
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Blood Adv. 2018 Jul 24;2(14):1765-1772
pubmed: 30037803
Leukemia. 2018 Jul;32(7):1493-1499
pubmed: 29445113
Leukemia. 2014 Aug;28(8):1657-65
pubmed: 24451410
J Clin Oncol. 2021 Nov 20;39(33):3737-3746
pubmed: 34406850
Blood Cancer Discov. 2022 Jul 6;3(4):316-329
pubmed: 35522837
BMC Hematol. 2018 Feb 1;18:4
pubmed: 29435332
Leukemia. 2021 Aug;35(8):2431-2434
pubmed: 33483614
J Clin Oncol. 2008 Jul 20;26(21):3607-13
pubmed: 18559873
Am J Hematol. 2017 Oct;92(10):1037-1046
pubmed: 28675513
J Clin Oncol. 2023 Jan 1;41(1):132-142
pubmed: 36054881
N Engl J Med. 2020 Oct 1;383(14):1358-1374
pubmed: 32997910
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Blood. 2018 Feb 15;131(7):818-821
pubmed: 29259002
Leuk Lymphoma. 2017 Jun;58(6):1325-1331
pubmed: 27774847
Ann Intern Med. 2020 Apr 21;172(8):513-522
pubmed: 32203980
Cell Stem Cell. 2021 Nov 4;28(11):1966-1981.e6
pubmed: 34473945
Lancet Oncol. 2017 Oct;18(10):1338-1347
pubmed: 28870615
J Clin Oncol. 2011 Jan 20;29(3):303-9
pubmed: 21149672
Lancet Haematol. 2018 Mar;5(3):e117-e126
pubmed: 29396092
Blood. 2008 Jan 15;111(2):574-82
pubmed: 17940203
J Clin Oncol. 2008 Dec 20;26(36):5943-9
pubmed: 19018091
Leukemia. 2016 Sep;30(9):1956-9
pubmed: 27133825
J Clin Oncol. 2012 Apr 20;30(12):1343-9
pubmed: 22370328
Blood. 2022 Jan 27;139(4):624-629
pubmed: 34758066
Blood. 2014 Oct 23;124(17):2705-12
pubmed: 25224413
Chemotherapy. 2019;64(5-6):238-247
pubmed: 32521534
Nat Genet. 2017 Feb;49(2):204-212
pubmed: 27992414
Leukemia. 2022 Nov;36(11):2739-2742
pubmed: 36104395
Future Oncol. 2021 Dec;17(36):5163-5175
pubmed: 34636250
J Clin Oncol. 2011 May 20;29(15):1971-9
pubmed: 21519010
N Engl J Med. 2010 Sep 9;363(11):1025-37
pubmed: 20825315
J Clin Oncol. 2021 May 10;39(14):1584-1594
pubmed: 33449813
Blood. 2021 Apr 15;137(15):2001-2009
pubmed: 33657207
Cancer. 2006 Apr 15;106(8):1794-803
pubmed: 16532500
N Engl J Med. 2021 Aug 12;385(7):640
pubmed: 34358421
Best Pract Res Clin Haematol. 2021 Mar;34(1):101245
pubmed: 33762100
Br J Haematol. 2022 Jan;196(2):268-269
pubmed: 34693518
JAMA. 2022 Sep 6;328(9):872-880
pubmed: 36066514
Blood. 2021 Jul 1;137(26):3685-3689
pubmed: 33690844
Blood. 2020 Aug 6;136(6):674-683
pubmed: 32285126
Front Oncol. 2022 Mar 31;12:866470
pubmed: 35433412
Blood. 2016 Mar 17;127(11):1387-97; quiz 1518
pubmed: 26702063
Blood Cancer J. 2022 Sep 7;12(9):132
pubmed: 36071048
Blood. 2016 Oct 6;128(14):1800-1813
pubmed: 27471235
Ann Hematol. 2019 Feb;98(2):339-350
pubmed: 30413901
Ann Oncol. 2021 Feb;32(2):142-156
pubmed: 33221366
Blood Adv. 2022 Apr 12;6(7):2219-2229
pubmed: 34933333
J Clin Oncol. 2021 May 10;39(14):1575-1583
pubmed: 33600210
Bone Marrow Transplant. 2022 Nov;57(11):1642-1648
pubmed: 35941354
Leukemia. 2012 Apr;26(4):855-8
pubmed: 21960245
J Clin Oncol. 2021 Apr 10;39(11):1223-1233
pubmed: 33539200
Br J Haematol. 2016 Dec;175(5):829-840
pubmed: 27650975
J Hematol Oncol. 2022 Aug 31;15(1):124
pubmed: 36045390
Leukemia. 2018 Dec;32(12):2648-2658
pubmed: 29895954
Leuk Lymphoma. 2017 May;58(5):1022-1036
pubmed: 27654579
Leukemia. 2019 Mar;33(3):785-790
pubmed: 30291338
Int J Mol Sci. 2022 Mar 03;23(5):
pubmed: 35269943
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668555
JCO Precis Oncol. 2021 Nov;5:107-122
pubmed: 34994594
Ann Hematol. 2020 Apr;99(4):677-692
pubmed: 32078008
J Natl Compr Canc Netw. 2022 Feb;20(2):106-117
pubmed: 35130502
Eur J Haematol. 2013 Apr;90(4):345-8
pubmed: 23336938
J Clin Oncol. 2007 Aug 10;25(23):3503-10
pubmed: 17687155
Cancer. 2014 Jun 15;120(12):1838-46
pubmed: 24706489
N Engl J Med. 2019 Sep 12;381(11):1011-1022
pubmed: 31340116
Ther Adv Hematol. 2021 Jul 16;12:20406207211032433
pubmed: 34349893
Blood Rev. 2018 Sep;32(5):368-377
pubmed: 29602612
Hemasphere. 2021 Nov 17;5(12):e661
pubmed: 34805767
N Engl J Med. 2006 Oct 5;355(14):1456-65
pubmed: 17021321
Am J Hematol. 2020 Nov;95(11):1399-1420
pubmed: 32744763
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
N Engl J Med. 2019 Sep 12;381(11):1001-1010
pubmed: 31340089
Cancer Cell. 2015 May 11;27(5):658-70
pubmed: 25920683
Lancet Haematol. 2020 Apr;7(4):e309-e319
pubmed: 32145771
Lancet Haematol. 2017 Mar;4(3):e127-e136
pubmed: 28162984
Blood. 2022 Jul 21;140(3):285-289
pubmed: 35507690
Am J Hematol. 2022 Feb 1;97(2):174-184
pubmed: 34724251
Ann Hematol. 2020 Mar;99(3):527-537
pubmed: 31989250
Blood. 2016 Aug 18;128(7):902-10
pubmed: 27335276
Blood. 2013 Sep 26;122(13):2286-8
pubmed: 24072851
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Blood. 2022 Nov 17;140(20):2170-2174
pubmed: 35797468
N Engl J Med. 2020 Jan 9;382(2):140-151
pubmed: 31914241
J Clin Oncol. 2011 May 20;29(15):1987-96
pubmed: 21483003
Leuk Res. 2021 Apr;103:106543
pubmed: 33640709
J Geriatr Oncol. 2020 Jan;11(1):114-120
pubmed: 31023599
J Clin Oncol. 2021 May 1;39(13):1426-1436
pubmed: 33764805
Br J Haematol. 2003 Mar;120(6):1037-46
pubmed: 12648074
Int J Mol Sci. 2021 Sep 18;22(18):
pubmed: 34576266
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):418-427
pubmed: 34889424
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Blood. 2009 Sep 17;114(12):2393-400
pubmed: 19564636
Ann Hematol. 2022 Aug;101(8):1689-1701
pubmed: 35488900
Lancet Haematol. 2019 Apr;6(4):e194-e203
pubmed: 30926081
Haematologica. 2012 Feb;97(2):e2
pubmed: 22298822
Leuk Res. 2018 Aug;71:89-91
pubmed: 30029156
Cancer. 2008 Sep 15;113(6):1351-61
pubmed: 18618511
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Hematol Oncol. 2022 Oct;40(4):812-817
pubmed: 35106810
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897